
    
      Phase 3, multicenter, global, three-arm, parallel design, placebo-controlled, double-blind,
      randomized study to determine efficacy, safety and tolerability of tafamidis on clinical
      outcomes (all-cause mortality and frequency of cardiovascular-related hospitalizations) in
      subjects with either transthyretin genetic variants or wild-type transthyretin resulting in
      amyloid cardiomyopathy.
    
  